http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103961683-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-01 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7076 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-708 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7068 |
| filingDate | 2014-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103961683-B |
| titleOfInvention | One treats dissimilar ametropic compound formulation |
| abstract | The present invention relates to one and can effectively treat the diseases such as myopia, hypermetropia, amblyopia and stravismus, and have no side effect, more the dissimilar ametropic compound formulation for the treatment of substantially not recurred after, it comprises the component of following parts by weight: inosine 1 ~ 3 part, ammonia peptide 35 ~ 45 parts, C14H25N4NaO11P2 3 ~ 12 parts, adenosine triphosphate disodium salt 0.3 ~ 1 part and Cerebrolysin Vial 0 ~ 0.3 part, wherein, eye ammonia peptide weight is equivalent to fresh buphthalmos ball weight in described eye ammonia peptide；Cerebrolysin Vial weight is with total nitrogen weighing scale.Invention formulation proves through a large amount of clinical trials, obvious effective rate 100%, and cure rate more than 90% contrasts with each one-component, obvious difference, has successfully filled up the blank of each disease drug treatment of eye ametropia. |
| priorityDate | 2014-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 25.